

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/735461-Conf. #3119
	Filing Date	December 11, 2003
	First Named Inventor	Michael P. CZECH
	Art Unit	1635
	Examiner Name	J.B. Ashen
Total Number of Pages in This Submission	Attorney Docket Number	UMY-055

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Return Receipt Postcard Copies of Thirty-three (33) References
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input checked="" type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	LAHIVE & COCKFIELD, LLP		
Signature			
Printed name	Debra J. Milasincic		
Date	November 8, 2005	Reg. No.	46,931

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 8, 2005

Signature:

(Debra J. Milasincic)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 8, 2005 Signature: _____

(Debra J. Milasincic)

Docket No.: UMY-055
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Michael P. Czech *et al.*

Application No.: 10/735461

Confirmation No.: 3119

Filed: December 11, 2003

Art Unit: 1635

For: METHOD OF INTRODUCING siRNA INTO
ADIPOCYTES

Examiner: J.B. Ashen

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. UMY-055. A duplicate copy of this paper is enclosed.

Dated: November 8, 2005

DJM/JAM/mch

Respectfully submitted,

By 

Debra J. Milasincic

Registration No.: 46,931

LAHIVE & COCKFIELD, LLP


28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735461-Conf. #3119
		Filing Date	December 11, 2003
		First Named Inventor	Michael P. CZECH
		Art Unit	1635
		Examiner Name	J.B. Ashen
Sheet 1 of 2	Attorney Docket Number	UMY-055	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C1	Alessi, Dario, et al., "3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase," <i>Current Biology</i> , Vol. 7:776-789 (1997)			
	C2	Brazil, Derek P., et al., "Ten years of protein kinase B signalling: a hard Akt to follow," <i>Trends in Biochemical Sciences</i> , Vol. 26(11):657-664 (2001)			
	C3	Brummelkamp, Thijn R., et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," <i>Science</i> , Vol. 296:550-553 (2002)			
	C4	Calegari, Federica, et al., "Tissue-specific RNA interference in postimplantation mouse embryos with endoribonuclease-prepared short interfering RNA," <i>PNAS</i> , Vol. 99(22):14236-14240 (2002)			
	C5	Calera, Monica R., et al., "Insulin Increases the Association of Akt-2 with Glut4-containing Vesicles," <i>The Journal of Biological Chemistry</i> , Vol. 273(13):7201-7204 (1998)			
	C6	Chiu, Ya-Lin, et al., "RNAi in Human Cells: Basic Structural and Functional Features of Small Interfering RNA," <i>Molecular Cell</i> , Vol. 10:549-561 (2002)			
	C7	Cho, Han, et al., "Akt1/PKB α Is Required for Normal Growth but dispensable for Maintenance of Glucose Homeostasis in Mice," <i>The Journal of Biological Chemistry</i> , Vol. 276(42):38349-38352 (2001)			
	C8	Cho, Han, et al., "Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKB β)," <i>Science</i> , Vol. 292:1728-1731 (2001)			
	C9	Cohen, Philip, et al., "The renaissance of GSK3," <i>Molecular Cell Biology</i> , Vol. 2:769-776 (2001)			
	C10	Cross, Darren A.E., et al., "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B," <i>Nature</i> , Vol. 378:785-789 (1995)			
	C11	Elbashir, Sayda M., et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> , Vol. 411:494-498 (2001)			
	C12	Harrison, Scott A., et al., "Insulin Regulation of Hexose Transport in Mouse 3T3-L1 Cells Expressing the Human HepG2 Glucose Transporter," <i>The Journal of Biological Chemistry</i> , Vol. 265(33):20106-20116 (1990)			
	C13	Hill, Michelle M., et al., "A Role for Protein Kinase B β /Akt2 in Insulin-Stimulated GLUT4 Translocation in Adipocytes," <i>Molecular and Cellular Biology</i> , Vol. 19(11):7771-7781 (1999)			
	C14	Kohn, Aimee D., et al., "Expression of a Constitutively Active Akt Ser/Thr Kinase in 3T3-L1 Adipocytes Stimulates Glucose Uptake and Glucose Transporter 4 Translocation," <i>The Journal of Biological Chemistry</i> , Vol. 271(49):31372-31378 (1996)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--


Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/735461-Conf. #3119
				Filing Date	December 11, 2003
				First Named Inventor	Michael P. CZECH
				Art Unit	1635
				Examiner Name	J.B. Ashen
Sheet	2	of	2	Attorney Docket Number	UMY-055

C15	Kotani, Ko, et al., "Requirement of Atypical Protein Kinase C λ for Insulin Stimulation of Glucose Uptake but Not for Akt Activation in 3T3-L1 Adipocytes," <i>Molecular and Cellular Biology</i> , Vol. 18(12):6971-6982 (1998)	
C16	Lee, Nan Sook, et al., "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells," <i>nature biotechnology</i> , Vol. 19:500-505 (2002)	
C17	Lewis, David L., "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," <i>nature genetics</i> , Vol. 32:107-108 (2002)	
C18	McManus, Michael T., "Gene silencing using micro-RNA designed hairpins," <i>RNA</i> , Vol. 8:842-850 (2002)	
C19	Miyagishi, Makoto, et al., "U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells," <i>nature biotechnology</i> , Vol. 19:497-500 (2002)	
C20	Okabe, Masataka, et al., "Translational repression determines a neuronal potential in Drosophila asymmetric cell division," <i>Nature</i> , Vol. 411:94-98 (2001)	
C21	Paddison, Patrick J., et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells," <i>Genes & Development</i> , Vol. 16:948-958 (2002)	
C22	Paul, Cynthia P., et al., "Effective expression of small interfering RNA in human cells," <i>nature biotechnology</i> , Vol. 29:505-508 (2002)	
C23	Scherr, Michaela, et al., "Gene Silencing Mediated by Small Interfering RNAs in Mammalian Cells," <i>Current Medicinal Chemistry</i> , Vol. 10:245-256 (2003)	
C24	Sharp, Phillip A., "RNA interference - 2001," <i>Genes & Development</i> , Vol. 15:485-490 (2001)	
C25	Spiller, David G., et al., "Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation," <i>Blood</i> , Vol. 91(12):4738-4746 (1998)	
C26	Sui, Guangchao, et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," <i>PNAS</i> , Vol. 99(8):515-5520 (2002)	
C27	Summers, Scott A., et al., "Differentiation-dependent Suppression of Platelet-derived Growth Factor Signaling in Cultured Adipocytes," <i>The Journal of Biological Chemistry</i> , Vol. 274(34):23858-23867 (1999)	
C28	Tuschl, Thomas, "Expanding small RNA interference," <i>nature biotechnology</i> , Vol. 20:446-448 (2002)	
C29	Ueki, Kohjiro, et al., "Potential Role of Protein Kinase B in Insulin-induced Glucose Transport, Glycogen Synthesis, and Protein Synthesis," <i>The Journal of Biological Chemistry</i> , Vol. 273(9):5315-5322 (1998)	
C30	Wang, Qinghua, et al., "Protein Kinase B/Akt Participates in GLUT4 Translocation by Insulin in L6 Myoblasts," <i>Molecular and Cellular Biology</i> , Vol. 19(6):4008-4018 (1999)	
C31	Williams, Michayla R., et al., "The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells," <i>Current Biology</i> , Vol. 10:439-448 (2000)	
C32	Yu, Jenn-Yah, et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells," <i>PNAS</i> , Vol. 99(9):6047-6052 (2002)	
C33	Zeng, Yan, et al., "Both natural and Designated Micro RNAs Can Inhibit the Expression of Cognate mRNAs When Expressed in Human Cells," <i>Molecular Cell</i> , Vol. 9:1327-1333 (2002)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/735461


Attorney Docket No.: UMY-055

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on November 8, 2005
Date


Signature

Debra J. Milasincic

Typed or printed name of person signing Certificate

46,931
Registration Number, if applicable

(617) 227-7400
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal
Information Disclosure Statement
IDS (Citation) by Applicant (33 References)
Copies of Thirty-three (33) References Return Receipt Postcard